RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2004; 92(04): 886-887
DOI: 10.1055/s-0037-1614196
DOI: 10.1055/s-0037-1614196
Case Report
Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration
Weitere Informationen
Publikationsverlauf
Received
06. Februar 2004
Accepted after revision
04. Juli 2004
Publikationsdatum:
15. Dezember 2017 (online)
-
References
- 1 Moake JL. Thrombotic microangiopathies. NEJM 2002; 347: 589-600.
- 2 Veyradier A, Obert B, Houllier A. et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72.
- 3 McCarthy LJ, Danielson CF, Miraglia C. et al. Platelet transfusion and thrombotic thrombocytopenia purpura. Transfusion 2003; 43: 829-30.
- 4 Bell RW, Hayden BG, Paul MN. et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Clinical experience in 108 patients. NEJM 1991; 325: 398-403.
- 5 Lind SE. Thrombocytopenic purpura and platelet transfusion (letter). Ann Intern Med 1987; 106: 478.
- 6 Harkness DR, Byrnes JJ, Lian EC. et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981; 246: 1931-3.
- 7 Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987; 24: 194-201.
- 8 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997; 90: 2515-20.
- 9 Borchielline A, Fijnvandraat K, ten Cate JW. et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 15: 2951-8.
- 10 Vischer UM, Ingerslev J, Wollhein CB. et al. Acute von Willebrand factor secretion from endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb Haemost 1997; 77: 387-93.
- 11 Moake JL, Turner NA, Stathopouls NA. et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-61.
- 12 Sakariassen KS, Cattaneo M, Berg A. et al. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229-36.
- 13 Stratton J, Warwicker P, Watkins S. et al. Desmopressin may be hazardous in thrombotic microangiopathy. Nephrol Dial Transplant 2001; 16: 161-2.
- 14 Tsai H, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. NEJM 1998; 339: 1585-94.
- 15 Hartmann S, Reinhart W. Fatal complication of desmopressin. Lancet 1995; 345: 1302-3.
- 16 Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hem 1988; 28: 63-5.
- 17 Albert SG, Salvato-Lechner V, Joist JH. Venous thromboembolism and transient thrombocytopenia in a patient with diabetes insipidus treated with desmopressin acetate (DDAVP). Thrombosis Research 1988; 50: 695-705.
- 18 Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989; 16: 675-6.
- 19 Flordal PA, Ljungstrom K, Fehrm A. Desmopressin and postoperative thromboembolism. Thrombosis Research 1992; 68: 429-33.
- 20 Czer LSC, Bateman TM, Gray PJ. et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Cell Cardiol 1987; 09: 1139-47.